Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1996 2
1999 1
2006 1
2007 2
2008 2
2009 5
2010 10
2011 5
2012 6
2013 8
2014 4
2015 4
2016 5
2017 3
2018 7
2019 11
2020 15
2021 16
2022 8
2023 6
2024 3
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.
Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, Mastronuzzi A, Cefalo MG, Pagliara D, Amicucci M, Li Pira G, Leone G, Bertaina V, Sinibaldi M, Di Cecca S, Guercio M, Abbaszadeh Z, Iaffaldano L, Gunetti M, Iacovelli S, Bugianesi R, Macchia S, Algeri M, Merli P, Galaverna F, Abbas R, Garganese MC, Villani MF, Colafati GS, Bonetti F, Rabusin M, Perruccio K, Folsi V, Quintarelli C, Locatelli F; Precision Medicine Team–IRCCS Ospedale Pediatrico Bambino Gesù. Del Bufalo F, et al. Among authors: de angelis b. N Engl J Med. 2023 Apr 6;388(14):1284-1295. doi: 10.1056/NEJMoa2210859. N Engl J Med. 2023. PMID: 37018492
Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL.
Del Bufalo F, Becilli M, Rosignoli C, De Angelis B, Algeri M, Hanssens L, Gunetti M, Iacovelli S, Li Pira G, Girolami E, Leone G, Lazzaro S, Bertaina V, Sinibaldi M, Di Cecca S, Iaffaldano L, Künkele A, Boccieri E, Del Baldo G, Pagliara D, Merli P, Carta R, Quintarelli C, Locatelli F. Del Bufalo F, et al. Among authors: de angelis b. Blood. 2023 Jul 13;142(2):146-157. doi: 10.1182/blood.2023020023. Blood. 2023. PMID: 37172203 Free article.
Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies.
Manni S, Del Bufalo F, Merli P, Silvestris DA, Guercio M, Caruso S, Reddel S, Iaffaldano L, Pezzella M, Di Cecca S, Sinibaldi M, Ottaviani A, Quadraccia MC, Aurigemma M, Sarcinelli A, Ciccone R, Abbaszadeh Z, Ceccarelli M, De Vito R, Lodi MC, Cefalo MG, Mastronuzzi A, De Angelis B, Locatelli F, Quintarelli C. Manni S, et al. Among authors: de angelis b. Nat Commun. 2023 Jun 9;14(1):3423. doi: 10.1038/s41467-023-38723-y. Nat Commun. 2023. PMID: 37296093 Free PMC article.
GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.
Ciccone R, Quintarelli C, Camera A, Pezzella M, Caruso S, Manni S, Ottaviani A, Guercio M, Del Bufalo F, Quadraccia MC, Orlando D, Di Cecca S, Sinibaldi M, Aurigemma M, Iaffaldano L, Sarcinelli A, D'Amore ML, Ceccarelli M, Nazio F, Marabitti V, Giorda E, Pezzullo M, De Stefanis C, Carai A, Rossi S, Alaggio R, Del Baldo G, Becilli M, Mastronuzzi A, De Angelis B, Locatelli F. Ciccone R, et al. Among authors: de angelis b. Clin Cancer Res. 2024 Jun 3;30(11):2545-2557. doi: 10.1158/1078-0432.CCR-23-1880. Clin Cancer Res. 2024. PMID: 38551501 Free PMC article.
MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting.
Pomella S, Cassandri M, D'Archivio L, Porrazzo A, Cossetti C, Phelps D, Perrone C, Pezzella M, Cardinale A, Wachtel M, Aloisi S, Milewski D, Colletti M, Sreenivas P, Walters ZS, Barillari G, Di Giannatale A, Milano GM, De Stefanis C, Alaggio R, Rodriguez-Rodriguez S, Carlesso N, Vakoc CR, Velardi E, Schafer BW, Guccione E, Gatz SA, Wasti A, Yohe M, Ignatius M, Quintarelli C, Shipley J, Miele L, Khan J, Houghton PJ, Marampon F, Gryder BE, De Angelis B, Locatelli F, Rota R. Pomella S, et al. Among authors: de angelis b. Nat Commun. 2023 Dec 15;14(1):8373. doi: 10.1038/s41467-023-44130-0. Nat Commun. 2023. PMID: 38102140 Free PMC article.
Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma.
Quintarelli C, Del Bufalo F, De Ioris MA, Guercio M, Algeri M, Pagliara D, Silvestris DA, Di Nardo M, Sinibaldi M, Di Cecca S, Iaffaldano L, Manni S, Fustaino V, Garganese MC, Colafati GS, Bertaina V, Becilli M, Mastronuzzi A, Fabozzi F, Gunetti M, Iacovelli S, Bugianesi R, Macchia S, Li Pira G, Cefalo MG, Leone G, Del Baldo G, De Angelis B, Locatelli F. Quintarelli C, et al. Among authors: de angelis b. Nat Med. 2025 Mar;31(3):849-860. doi: 10.1038/s41591-024-03449-x. Epub 2025 Jan 15. Nat Med. 2025. PMID: 39815015
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells.
Pezzella M, Quintarelli C, Quadraccia MC, Sarcinelli A, Manni S, Iaffaldano L, Ottaviani A, Ciccone R, Camera A, D'Amore ML, Di Cecca S, Sinibaldi M, Guercio M, Aurigemma M, De Falco P, Fustaino V, Rota R, Pomella S, Cassandri M, Di Giannatale A, Agrati C, Bordoni V, Guarracino F, Massa M, Del Baldo G, Becilli M, Milano GM, Del Bufalo F, Locatelli F, De Angelis B. Pezzella M, et al. Among authors: de angelis b. J Hematol Oncol. 2024 Dec 18;17(1):127. doi: 10.1186/s13045-024-01641-7. J Hematol Oncol. 2024. PMID: 39695851 Free PMC article.
GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.
Locatelli F, Pagliara D, De Ioris MA, Becilli M, Del Baldo G, Serra A, Mastronuzzi A, Cefalo MG, Li Pira G, Leone G, Bertaina V, Fabozzi F, Di Nardo M, Rosignoli C, D'Andrea ML, Crocoli A, Vennarini S, Sinibaldi M, Di Cecca S, Guercio M, Iaffaldano L, Lucarelli B, Algeri M, Merli P, Colafati GS, De Angelis B, Quintarelli C, Del Bufalo F. Locatelli F, et al. Among authors: de angelis b. Nat Med. 2025 Aug 21. doi: 10.1038/s41591-025-03874-6. Online ahead of print. Nat Med. 2025. PMID: 40841488
HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaks.
Cassandri M, Porrazzo A, Pomella S, Noce B, Zwergel C, Aiello FA, Vulcano F, Milazzo L, Camero S, Pajalunga D, Spada M, Manzi V, Gravina GL, Codenotti S, Piccione M, Tomaciello M, Signore M, Barillari G, Marchese C, Fanzani A, De Angelis B, Quintarelli C, Vakoc CR, Chen EY, Megiorni F, Locatelli F, Valente S, Mai A, Rota R, Marampon F. Cassandri M, et al. Among authors: de angelis b. Cell Death Discov. 2024 Aug 6;10(1):351. doi: 10.1038/s41420-024-02115-y. Cell Death Discov. 2024. PMID: 39107280 Free PMC article.
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia.
Caruso S, De Angelis B, Del Bufalo F, Ciccone R, Donsante S, Volpe G, Manni S, Guercio M, Pezzella M, Iaffaldano L, Silvestris DA, Sinibaldi M, Di Cecca S, Pitisci A, Velardi E, Merli P, Algeri M, Lodi M, Paganelli V, Serafini M, Riminucci M, Locatelli F, Quintarelli C. Caruso S, et al. Among authors: de angelis b. J Hematol Oncol. 2022 Nov 5;15(1):163. doi: 10.1186/s13045-022-01376-3. J Hematol Oncol. 2022. PMID: 36335396 Free PMC article.
115 results